Author(s)

Rodrigo Arrangoiz^*, Fernando Cordera, David Caba, Eduardo Moreno, Enrique Luque-de-Leon, Manuel Muñoz

Sociedad Quirúrgica S.C., American British Cowdray Medical Center, Mexico City, Mexico.

Thyroid tumors include those that originate from follicular cells and those that arise from parafollicular cells (C cells). Differentiated thyroid cancer, which originates from follicular cells, includes papillary carcinoma, follicular carcinoma, oncocytic cell carcinoma (Hürthle), poorly differentiated carcinoma, and anaplastic carcinoma. The incidence of thyroid cancer has been increasing significantly, with an estimated incidence in the United States of America of 53,990 cases by the year 2018. This neoplasm is listed as the most common endocrine tumor and represents approximately 3% of all malignant tumors in humans, with 75% of cases occurring in women, and two-thirds of cases occurring in people under 55 years. The increase in the prevalence/incidence of low-risk thyroid cancer over the last 10 to 20 years has required a re-appraisal of the standard one-size-fits-all approach to differentiated thyroid cancer. This adaptation to a more individualized management of the patient with thyroid cancer has led to a much more risk-adapted approach to the diagnosis, initial therapy, adjuvant therapy, and follow-up of patients with differentiated thyroid cancer. This paper with review the current understanding of the clinical presentation, diagnostic workup, and management of thyroid cancer centered on evidence-based and personalized medicine.

Thyroid Nodules, Thyroid Cancer, Thyroid FNA, Thyroid Nodule Workup, Thyroid Cancer Treatment, Molecular Studies for Thyroid Cancer

Arrangoiz, R. , Cordera, F. , Caba, D. , Moreno, E. , Luque-de-Leon, E. and Muñoz, M. (2019) Thyroid Cancer. International Journal of Otolaryngology and Head & Neck Surgery, 8, 217-270. doi: 10.4236/ijohns.2019.86024.